Designed for Risk Reduction, Optimal Performance, and Patient Safety
WAYNE, Pa.--(BUSINESS WIRE)--Jul. 24, 2017--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
technologies for critical care and surgery, has announced today that its
Arrow® Seldinger Arterial Catheterization Device received
market clearance from the U.S. Food and Drug Administration (FDA).
The new Seldinger Arterial Catheterization Device is indicated for
short-term use. The device is designed to improve patient safety by
eliminating confusion of catheter identification, reduce risk of
complications associated with insertion technique, and provide optimal
diagnostics leading to effective treatment for patients. Multiple sizes
are available to provide customization to each patient, each insertion
site, and each application.
“As we continue to discover new and innovative solutions, the Seldinger
Arterial Catheterization Device is now part of our extensive arterial
offering in the U.S. market,” said Jake Newman, Vice President and
General Manager of Teleflex's Vascular Access Division. “This innovative
device is intended to facilitate ease of insertion and resistance to
Teleflex expects to launch the Arrow® Seldinger Arterial
Catheterization Device in the United States this year.
To learn more about the Arrow® Vascular portfolio from
Teleflex, please visit teleflex.com/usa/product-areas/vascular-access/.
About Teleflex Incorporated
Teleflex is a global provider of
medical technologies designed to improve the health and quality of
people’s lives. We apply purpose driven innovation – a relentless
pursuit of identifying unmet clinical needs – to benefit patients and
healthcare providers. Our portfolio is diverse, with solutions in the
fields of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care. Teleflex
employees worldwide are united in the understanding that what we do
every day makes a difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson
RCI®, LMA®, Pilling®, Rusch®
and Weck® – trusted brands united by a common sense of
Any statements contained in this
press release that do not describe historical facts may constitute
forward-looking statements. Any forward-looking statements contained
herein are based on our management's current beliefs and expectations,
but are subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these statements.
These risks and uncertainties are identified and described in more
detail in our filings with the Securities and Exchange Commission,
including our Annual Report on Form 10-K.
1. Teleflex. Seldinger Arterial Catheter
Benchtop Studies. Data on File, D011453: 2014.
Teleflex, the Teleflex logo, and Arrow are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries.
© 2017 Teleflex Incorporated. All rights reserved. MC-003596
View source version on businesswire.com: http://www.businesswire.com/news/home/20170724005075/en/
Source: Teleflex Incorporated
Jake Elguicze, 610-948-2836
and Vice President, Investor Relations